Literature DB >> 29464448

Development and validation of an algorithm to identify drug-induced anaphylaxis in the Beijing Pharmacovigilance Database.

Ying Zhao1,2,3, Haidong Lu4, Sydney Thai4, Xiaotong Li1,3, John Hui5, Huilin Tang6, Suodi Zhai1, Lulu Sun7,8, Tiansheng Wang9,10.   

Abstract

Background Pharmacovigilance databases are utilized to identify serious adverse drug events (ADEs). In China, very few studies have evaluated the validity of using pharmacovigilance databases to identify drug-induced anaphylaxis (DIA). Objective We aimed to develop and validate an algorithm to identify DIA using the Beijing Pharmacovigilance Database (BPD). Setting ADEs from the BPD mainly spontaneously reported from 94 hospitals in Beijing, China. Method Using the diagnoses, we developed an algorithm to identify potential DIAs from the BPD between January 2004 and December 2014. A sample of 500 patients was randomly selected for chart abstraction. Two physician adjudicators assessed whether DIA occurred using the published clinical criteria as the gold standard. Main outcome measure Positive predictive values (PPVs) and 95% confidence intervals of the algorithm and algorithm criteria components were calculated. Results 500 patients (53.2% female; the mean age 48.2 years) with potential DIA were selected using the algorithm. 444 were adjudicated as having anaphylaxis by physicians. The PPV of the overall algorithm was 88.8% (95% CI 86.0-91.6%). PPV for the algorithm only using specific diagnoses of "anaphylactic shock", "anaphylactic reaction", and "anaphylactoid reaction [severe]" was 89.6% (95% CI 86.6-92.4%); this partial algorithm identified 387 (87.2%) DIAs. The diagnosis that identified the most DIAs (83.8%) was "anaphylactic shock", with a PPV of 91.6% (95% CI 88.9-94.3%). Conclusion The overall algorithm identified a greater number of DIAs than the algorithm that only used specific diagnoses; however, its PPV was slightly lower. We were able to identify DIAs with the algorithm we developed.

Entities:  

Keywords:  Algorithm; Anaphylaxis; China; Pharmacoepidemiology; Pharmacovigilance; Positive predictive value; Validation

Mesh:

Year:  2018        PMID: 29464448     DOI: 10.1007/s11096-018-0594-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  28 in total

1.  Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database.

Authors:  Tiansheng Wang; Xiang Ma; Yan Xing; Shusen Sun; Hua Zhang; Til Stürmer; Bin Wang; Xiaotong Li; Huilin Tang; Ligong Jiao; Suodi Zhai
Journal:  Int Arch Allergy Immunol       Date:  2017-05-16       Impact factor: 2.749

2.  Temporal Trends in Epinephrine Dispensing and Allergy/Immunology Follow-up Among Emergency Department Anaphylaxis Patients in the United States, 2005-2014.

Authors:  Megan S Motosue; M Fernanda Bellolio; Holly K Van Houten; Nilay D Shah; Venkatesh R Bellamkonda; David M Nestler; Ronna L Campbell
Journal:  J Allergy Clin Immunol Pract       Date:  2017-07-26

3.  Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System.

Authors:  Marianne Phelan Ross; Martine Ferguson; Debra Street; Karl Klontz; Tom Schroeder; Stefano Luccioli
Journal:  J Allergy Clin Immunol       Date:  2008-01       Impact factor: 10.793

4.  Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority.

Authors:  Inês Ribeiro-Vaz; Joana Marques; Pascal Demoly; Jorge Polónia; Eva Rebelo Gomes
Journal:  Eur J Clin Pharmacol       Date:  2012-08-23       Impact factor: 2.953

5.  Population-based drug-related anaphylaxis in children and adolescents captured by South Carolina Emergency Room Hospital Discharge Database (SCERHDD) (2000-2002).

Authors:  Suzanne L West; Aimee A D'Aloisio; Tamar Ringel-Kulka; Anna E Waller; W Clayton Bordley
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-12       Impact factor: 2.890

6.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.

Authors:  N J Brown; W A Ray; M Snowden; M R Griffin
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

7.  Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel.

Authors:  Kathleen E Walsh; Sarah L Cutrona; Sarah Foy; Meghan A Baker; Susan Forrow; Azadeh Shoaibi; Pamala A Pawloski; Michelle Conroy; Andrew M Fine; Lise E Nigrovic; Nandini Selvam; Mano S Selvan; William O Cooper; Susan Andrade
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-09-05       Impact factor: 2.890

8.  Appropriateness of epinephrine use in ED patients with anaphylaxis.

Authors:  Damian V Baalmann; John B Hagan; James T C Li; Erik P Hess; Ronna L Campbell
Journal:  Am J Emerg Med       Date:  2015-10-09       Impact factor: 2.469

9.  Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology.

Authors:  A Muraro; G Roberts; M Worm; M B Bilò; K Brockow; M Fernández Rivas; A F Santos; Z Q Zolkipli; A Bellou; K Beyer; C Bindslev-Jensen; V Cardona; A T Clark; P Demoly; A E J Dubois; A DunnGalvin; P Eigenmann; S Halken; L Harada; G Lack; M Jutel; B Niggemann; F Ruëff; F Timmermans; B J Vlieg-Boerstra; T Werfel; S Dhami; S Panesar; C A Akdis; A Sheikh
Journal:  Allergy       Date:  2014-06-09       Impact factor: 13.146

10.  Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data.

Authors:  Yan Xing; Hua Zhang; Shusen Sun; Xiang Ma; Roy A Pleasants; Huilin Tang; Hangci Zheng; Suodi Zhai; Tiansheng Wang
Journal:  Eur J Pediatr       Date:  2017-11-22       Impact factor: 3.183

View more
  3 in total

Review 1.  Pharmacovigilance in China: development and challenges.

Authors:  Ying Zhao; Tiansheng Wang; Guangyao Li; Shusen Sun
Journal:  Int J Clin Pharm       Date:  2018-07-26

2.  Overview of this issue: pharmacovigilance, what is new?

Authors:  Linda Gore Martin; Yolande Hanssens; Vibhu Paudyal
Journal:  Int J Clin Pharm       Date:  2018-08

Review 3.  Intelligent Telehealth in Pharmacovigilance: A Future Perspective.

Authors:  Heba Edrees; Wenyu Song; Ania Syrowatka; Aurélien Simona; Mary G Amato; David W Bates
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.